Company profile
Astellas Pharma Inc.
Pipeline18 assets
- zolbetuximabIMAB362 / VYLOY / Claudin 18.2 / Antibody / OncologyGastric and gastroesophageal junction adenocarcinoma, combo with pembrolizumab and chemotherapyFiledEuropeJapan
- gilteritinibASP2215 / XOSPATA / FLT3 / Small molecule / OncologyNewly diagnosed acute myeloid leukemia with high intensity induction chemotherapyPhase 3Post-chemotherapy maintenance acute myeloid leukemiaPhase 3Post-hematopoietic stem cell transplant maintenance acute myeloid leukemiaPhase 3
- enfortumab vedotinASG-22ME / PADCEV / Nectin-4 / Antibody-drug conjugate (ADC) / OncologyCisplatin-eligible muscle-invasive bladder cancer, combo with pembrolizumabFiledEuropeUSCisplatin-ineligible muscle-invasive bladder cancer, combo with pembrolizumabFiledEuropeJapanBladder-sparing muscle-invasive bladder cancer, combo with pembrolizumabPhase 2
- fezolinetantESN364 / VEOZAH / NK3 receptor / Small molecule / Women's HealthVasomotor symptoms due to menopausePhase 3ChinaVasomotor symptoms in breast cancer patients on adjuvant endocrine therapyPhase 2
- zocaglusagene nuzaparvovecAT845 / GAA gene replacement / Gene therapy (AAV-based gene therapy) / Genetic RegulationPompe diseasePhase 1
- ASP2957ASP2957 / MTM1 gene replacement / Gene therapy (AAV-based gene therapy) / Genetic RegulationX-linked myotubular myopathyPhase 1
- setidegrasibKRAS G12D / Small molecule degrader / Targeted Protein DegradationPancreatic ductal adenocarcinomaPhase 3
- ASP7317ASP7317 / Retinal pigment epithelial cells / Cell therapy / OphthalmologyGeographic atrophy secondary to age-related macular degenerationPhase 1
- ASP1002ASP1002 / Claudin 4/CD137 / T-cell engager bispecific antibody / OncologyGastric and gastroesophageal junction adenocarcinoma; pancreatic adenocarcinomaPhase 1
- ASP5834ASP5834 / Pan-KRAS / Small molecule degrader / OncologyCancerPhase 1
- VIR-5500VIR-5500 / PSMA/CD3 / T-cell engager / OncologyProstate cancerPhase 1
- ASP2998ASP2998 / TROP2 / Antibody-drug conjugate (ADC) / OncologyCancerPhase 1
- ASP2138ASP2138 / Claudin 18.2/CD3 / T-cell engager bispecific antibody / OncologyCancerPhase 2
- ASP546CASP546C / Claudin 18.2 / Antibody-drug conjugate (ADC) / OncologyCancerPhase 2Europe
- abiraterone decanoateASP5541/PRL-02 / CYP17 lyase / Small molecule / OncologyProstate cancerPhase 2
- mirabegronYM178 / Beta-3 receptor / Small molecule / UrologyNeurogenic detrusor overactivity in pediatric patients aged 6 months to less than 3 yearsPhase 3Europe
- roxadustatASP1517/FG-4592 / HIF-PH / Small molecule / NephrologyAnemia associated with chronic kidney disease in pediatric patientsPhase 3Europe
- pudexacianinium chlorideASP5354 / Drug-device combination / OtherIntraoperative ureter visualization for minimally invasive and open abdominopelvic surgeriesPhase 3
Latest news14 items
All newsAstellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
Presentation / Abstract • Phase 3ASCO oral presentation Fri, May 29, 2026, 2:45 PM CDT
IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients
Presentation / Abstract • Phase 3ARVO presentation Tue, May 12, 2026